The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
| Specialty Retail Industry | Consumer Discretionary Sector | Yongfeng Zhang CEO | XFRA Exchange | 03209R103 CUSIP |
| US Country | 1,976 Employees | - Last Dividend | - Last Split | - IPO Date |
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that focuses on the development, manufacturing, marketing, and sale of both generic and proprietary injectable, inhalation, and intranasal products. The company has a global footprint with operations in the United States, China, and France. Established in 1996 and based in Rancho Cucamonga, California, Amphastar Pharmaceuticals caters to a diverse range of medical needs, emphasizing solutions for severe hypoglycemia, opioid overdose, adrenocortical insufficiency, intermittent asthma, and deep vein thrombosis among others. Additionally, the company engages in the distribution of insulin APIs and is involved in the development of generic, biosimilar, and innovative analytical technologies.